Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7660756 | 0.79 | P2RX3 (0.47) | DHFRTP53SMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL16594355 | 0.77 | CA12 (0.50) | CA12CA1CA2CA9CA14 | |
| SCHEMBL14966328 | 0.77 | HDAC1 (0.50) | CA12CA1CA2CA9CA14 | |
| SCHEMBL9446061 | 0.76 | TLR8 (0.39) | TLR8TLR7SLC7A5ABCG2DHFR | |
| Hydrochloric Acid SCHEMBL5963878 | 0.76 | CA12 (0.49) | CA12CA1CA2CA9CA14 | |
| SCHEMBL2207588 | 0.76 | CYP4A11 (0.60) | CA12CA1CA2CA9CA14 | |
| SCHEMBL13891334 | 0.76 | PLK1 (0.51) | CA12CA1CA2CA9CA14 | |
| SCHEMBL4212803 | 0.75 | SIRT2 (0.43) | CA12CA1CA2CA9CA14 | |
| SCHEMBL7246822 | 0.75 | CA12 (0.48) | CA12CA1CA2CA9CA14 | |
| SCHEMBL31688879 | 0.75 | CYP4A11 (0.49) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6489333-B2 | HETEROCYCLIC COMPOUNDS CONTAINING A GUANIDINE MIMIC, FOR INHIBITION OF CELL ADHESION, TREATMENT OF ANGIOGENESIS DISORDERS, INFLAMMATION, CANCER METASTASIS, DIABETIC RETINOPATHY, THROMBOSIS, RESTENOSIS, MACULAR DEGENERATION | BRISTOL - MEYERS SQUIBB PHARMA COMPANY | 2002-12-03 | — | — | US | disclosed |
| US-20010044535-A1 | Integrin antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044535-A1 | Integrin antagonists | ITGB3, VCAM1, ITGB2 | CA12 4557/4885CA1 4714/4885CA2 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.